Rani Therapeutics is a San Jose, CA–based company developing The RaniPill™, a pill intended to replace injectable drug delivery for patients with chronic diseases. The company is led by founder and CEO Mir Imran and its research and technology originated at InCube Labs. Rani raised $53M in this round and said the funds will be used to invest in manufacturing in preparation for human clinical trials. To support the move to clinical testing it has hired Wilfredo Ortiz to lead day-to-day manufacturing operations and engaged Ray Diradoorian, former global head of manufacturing for Allergan, as a consultant. Rani is also working with a manufacturing automation company to develop the aseptic manufacturing line needed for human testing. The company reported the round brought total funding to $142M. Rani Therapeutics is a San Jose–based developer of technology to convert injectable drugs into oral pills and needle-free delivery systems for chronic disease therapies. The company raised $39M in a Series D round, bringing total funding to more than $100M. Investors in the round include GV (Google Ventures), Novartis, AstraZeneca, Cathay Ventures, Buttonwood, Crystal Horizon Investments, Pinemount Investments, the Pacific Venture Opportunity Fund, and Bossa Nova Investments. Rani plans to use the funds to accelerate clinical development of its platform, scale up manufacturing operations, and support human studies planned to start in 2018. It has partnerships with Novartis and AstraZeneca and is also testing additional biologics internally. Led by Chairman & CEO Mir Imran, Rani holds an IP portfolio with more than 100 patents, including 42 issued or allowed. Rani Therapeutics is developing a platform to enable oral delivery of injectable drugs including TNF-alpha inhibitors, interleukin antibodies, basal insulin and GLP-1. The company was founded in 2012 as a spinout of InCube Labs and is led by Chairman & CEO Mir Imran. Rani has entered strategic collaborations with Novartis and AstraZeneca/MedImmune to test its platform with selected drugs. The company intends to use its latest funding to expand the team, add new facilities and scale up manufacturing. Recently Rani hired Robert Gaffney as VP of Operations to lead expansion efforts. Rani is based in San Jose, CA. Rani Therapeutics is a San Jose, CA–based company that has developed a novel approach for the oral delivery of peptides, proteins and therapeutic antibodies. Led by Chairman & CEO Mir Imran, the company focuses on a route of administration intended to enable large biologics to be delivered into the bloodstream. Rani recently announced a collaboration with Novartis to run feasibility studies on delivering selected Novartis proprietary biologics using its platform. The company closed a Series C round of funding for an undisclosed amount and plans to use the proceeds to de‑risk the platform. Rani also intends to build the manufacturing infrastructure required for clinical trials and beyond. Rani Therapeutics is developing a platform to convert injectable drugs into oral pills. Its technology targets large drug molecules that currently require injection, including peptides, proteins, antibodies, RNAi therapies and select vaccines. The company specifically aims to enable oral delivery of drugs such as TNF-alpha inhibitors (e.g., adalimumab and etanercept) and basal insulin. It closed a Series B funding round of an undisclosed amount led by Google Ventures with participation from InCube Ventures and VentureHealth. Rani said it will use the proceeds to further develop its oral delivery approach. The company is led by chairman and CEO Mir Imran and is based in San Jose, California.

Total raised

$92M

Funding rounds

5

Latest round

Equity

Latest activity

Feb 2018